Skip to content

Moya Moya Syndrome With or Withtout Sickle Cell Disease

Descriptive Bicentric Study of Moya Moya Syndrome and Disease in Sickle Cell Disease Patients and Not Sickle Cell Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05050344
Acronym
BMM-ScD
Enrollment
50
Registered
2021-09-20
Start date
2021-05-01
Completion date
2022-12-01
Last updated
2021-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moya Moya Disease

Keywords

Moya Moya syndrome, Moya Moya

Brief summary

Moya Moya disease or syndrome ar characterized by a progressive or occlusion of the intracranial carotid arteries and their mainproximal branches, followed by the development of fragile neovessels at the base of the skull, leding to a high risk of both ischemic and hemorragic stroke over time. Moya Moya syndrome are associated to a variety of disease, which main frequent is sickle cell disease (SCD). Among patients with SCD who had suffered from at least one ischemic stroke, the prevalence of moya moya syndrome was estimated up to 43%. In general, therapeutic strategies in Moya Moya to prevent first ever ou recurrent stroke can be divided into conservative medical treatment and surgical revascularisation (direct bypass, indirect bypass or combined bypass). The aim of this study is to compare prognosis of patients with Moya Moya syndrome associated with sickle cell disease or not. The investigators retrospectiveluy analysed medical chart from 2010 to 2021 of patients with Moya Moya disease or syndrome at two French university hospitals (including a center of the french West Indies where prevalence of sickle cell disease is high). The diagnosis was based on angiography or MRI records showing uni- or bilateral stenosis of distal intracranial internal carotide arteries or middle cerebral arteries associated wirh classic collateral network. Main endpoint will be comparison of a composite outcome defined as time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement (defined by modified Rankin score \>2)

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \>=15 * patients at diagnosis of Moya Moya disease and syndrome

Exclusion criteria

* misclassified patients * clinical diagnosis of MM not confirmed by angiography or MRI

Design outcomes

Primary

MeasureTime frameDescription
time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement1 daycomposite endpoint of outcome defined as time from Moya Moya diagnosis to first or recurrent stroke or bad prognosis achivement (defined by modified Rankin score \>2)

Secondary

MeasureTime frameDescription
Time from MM diagnosis to Stroke1 dayTime from MM diagnosis to Stroke
poor prognosis or death1 daypoor prognosis or death (mRS\> 2) at the last clinical evaluation.

Countries

France

Contacts

Primary ContactNicolas Gaillard, MD
n-gaillard@chu-montpellier.fr4 67 33 74 13

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026